The 73 references in paper S. Al-Shukri Kh., M. Rybakova G., A. Lukyanov E., Yu. Ponomareva A., С. Аль-Шукри Х., М. Рыбакова Г., А. Лукьянов Э., Ю. Пономарева А. (2006) “ОНКОМАРКЕРЫ ПРИ ОПУХОЛЯХ ПОЧЕЧНОЙ ПАРЕНХИМЫ // ONCOMARKERS IN TUMORS OF RENAL PARENCHYMA” / spz:neicon:nefr:y:2006:i:1:p:77-85

1
Bostwick DC, Murphy GP Diagnosis and prognosis of renal cell carcinoma: highlights from an international consensus workgroup. Sem Urol Oncol 1998; 16: 46-52
(check this in PDF content)
2
Аль-Шукри СХ, Ткачук ВН. Опухоли мочеполовых ор­ ганов. СПб.: Питер, 2000; 60-78
(check this in PDF content)
3
Возианов АФ, Романенко АМ, Сайдакова НА и др. Экологический патоморфоз почечноклеточного рака в заг­ рязненных радионуклидами регионах Украины. Журн АМН Украины 2002; (1): 120-131
(check this in PDF content)
4
Brkovic D, Riedash G, Staehler G. Urologe A 1997; 36 (2): 103-108
(check this in PDF content)
5
Hafez KS,Novick AC, Campbell SC. Ibid 1997; 157 (4): 2067-2070
(check this in PDF content)
6
Klein EA, Novick AC. Comprehensive textbook of genitourinary oncology. Baltimore, 1996; 207-217
(check this in PDF content)
7
Lerner SE, Hawkinks CA, Blute ML et al. Parthial nephrectomy. J Urol 1996; 155 (2): 61-66
(check this in PDF content)
8
Степанов ВН, Колпаков ИС, Серегин АВ. Материалы 3-й Всероссийской научн. конф. «Консервативная хирур­ гия при опухоли почки» с участием стран СНГ М., 1999; 151­ 158
(check this in PDF content)
9
Kovacs G, Akhtar M, Beckwith BH. The Heidelberg classification of renal cell tumors. J Pathol 1999; 183: 131-135
(check this in PDF content)
10
Kovacs G. Molecular genetics and diagnosis of renal cell tumors. Urologe A 1999; 38: 433-441
(check this in PDF content)
11
Delahunt B. Histopathologic prognostic indicators for renal cell carcinoma. Semin Diagn Pathol 1998; 15: 68-76
(check this in PDF content)
12
Fuhrman SA, Lasky LS, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6: 655-663
(check this in PDF content)
13
Hemmerlein B, Markus A, Wehner M et al. Expression of acute and late-stage inflammatory antigens, c-fms, CSF-1, and human monocytic serine esterase 1, in tumor-associated m acrophages o f renal cell carcinom as. Cancer Immunol Immunother 2000; 49 (9): 485-492
(check this in PDF content)
14
Kowalczyk D, Skorupski W, Kwias Z, Nowak J. Flow cytom etric analysis o f tu m o u r-in filtra tin g lym phocytes in patients with renal cell carcinoma. Cancer Immunol Immunother 2001; 53 (5): 543-548
(check this in PDF content)
15
Shabtai M, Ye H, Frischer Z et al. Increased expression of activation m arkers in renal cell carcinom a in filtra tin g lymphocytes. J Urol 2002; 168 (5): 2216-2219
(check this in PDF content)
16
Zolota V, Tsamandas AC, M elachrinou M et al. Expression of CD44 protein in renal cell carcinomas: association with p53 expression. Urol Oncol 2002; 7(1): 13-17
(check this in PDF content)
17
Huang J, Soffer SZ, Kim ES et al. p53 accumulation in favo ra ble-histo lo gy W ilms tum or is associated with angiogenesis and clinically aggressive disease. J Pediatr Surg 2002; 37 (3): 523-527
(check this in PDF content)
18
Yoshioka K, Nakam ura S.Chrom osom e 9 and 17 aberrations and p53 gene deletion detected by fluorescence in situ hybridization in renal-cell carcinoma. Mol Urol 2001; 5 (1): 11-17
(check this in PDF content)
19
Hashimoto H, Sue Y, Saga Y et al. Roles of p53 and MDM2 in tumor proliferation and determination of the prognosis of transitional cell carcinoma of the renal pelvis and ureter. Int J Urol 2000; 7 (12): 457-463
(check this in PDF content)
20
Rioux-Leclercq N, Turlin B, Bansard J et al. Value of im m unohistochem ical Ki-67 and p53 determ inations as predictive factors of outcome in renal cell carcinoma. Urology 2000; 55 (4): 501-505
(check this in PDF content)
21
Haitel A, Wiener HG, Blaschitz U et al. Biologic behavior and p53 overexpression in multifocal renal cell carcinoma of clear cell type: an im m unohistochem ical study correlating grading, staging, and proliferation markers. Cancer 1999; 85 (4): 432-438
(check this in PDF content)
22
Chem eris G, Loktinov A, Rempel A et al. Elevated content of p53 protein in the absence of p53 gene mutations as a possible prognostic m arker for human renal cell tum ors. Virchows Arch 1995; 426 (6): 563-569
(check this in PDF content)
23
Ghanem MA, Van der Kwast TH, Den Hollander JC et al. The prognostic significance of apoptosis-associated proteins BCL-2, BAX and BCL-X in clinical nephroblastoma. J Cancer 2001;85 (10): 1557-1563
(check this in PDF content)
24
Paraf F, Gogusev J, Chretien Y, Droz D. Expression of bcl-2 oncoprotein in renal cell tumours. J Pathol 1995; 177 (3): 247-252
(check this in PDF content)
25
Chandler D, el-Naggar AK, Brisbay S et al. Apoptosis and expression of the bcl-2 proto-oncogene in the fetal and adult human kidney: evidence for the contribution of bcl-2 expression to renal carcinogenesis. Hum Pathol 1994; 25 (8): 789-796
(check this in PDF content)
26
Velickovic M, Delahunt B, M cIver B, Grebe SK. Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis. Mod Pathol 200; 15 (5): 479-485
(check this in PDF content)
27
Brenner W, Farber G, Herget T et al. Loss of tum or suppressor protein PTEN during renal carcinogenesis. Int J Cancer 2002 May; 99 (1): 53-57
(check this in PDF content)
28
Haitel A, Wiener HG, Neudert B et al. Expression of the cell cycle proteins p21, p27, and pRb in clear cell renal cell carcinoma and their prognostic significance. Urology 2001; 58 (3): 477-481
(check this in PDF content)
29
Yokogi H. Flow cytometric quantitation of the proliferation- associated nuclear antigen p105 and DNA content in patients with renal cell carcinoma. Cancer 1996;78 (4): 819-826
(check this in PDF content)
30
Leroy X, Zerimech F, Zini L et al. MUC1 expression is correlated with nuclear grade and tum or progression in pT1 renal clear cell carcinoma. Am J Clin Pathol 2002; 118 (1): 47-51
(check this in PDF content)
31
Kraus S, Abel PD, Nachtmann C et al. MUC1 mucin and trefoil factor 1 protein expression in renal cell carcinom a: correlation with prognosis. Hum Pathol 2002; 33 (1): 60-67
(check this in PDF content)
32
Fujita K, Denda K, Yamamoto M et al. Expression of MUC1 mucins inversely correlated with post-surgical survival of renal cell carcinoma patients. Br J Cancer 1999;80 (1-2): 301-308
(check this in PDF content)
33
Rotter M, Block T, Busch R et al. Expression of HER-2/ neu in renal-cell carcinoma. Correlation with histologic subtypes and differentiation. J Cancer 1992; 52 (2): 213-217
(check this in PDF content)
34
Fontana LO, Garcia Garcia F, Arcas Martinez Salas I et al. The expression o f p53 and c -e rb -2 in transitional cell carcinoma of the kidney pelvis and ureter and its relation to tumor progression and survival. Arch Esp Urol 2002; 55(7): 792­ 796
(check this in PDF content)
35
Ramp U, Bretschneider U, Ebert T et al. Prognostic im plications of CD95 receptor expression in clear cell renal carcinomas. Hum Pathol 2003; 34 (2): 174-179
(check this in PDF content)
36
Rasmuson T, Grankvist K, Jacobsen J, Ljungberg B. Impact of serum basic fibroblast growth factor on prognosis in human renal cell carcinoma. Eur J Cancer 2001; 37 (17): 2199-2203
(check this in PDF content)
37
Dosquet C, Coudert MC, Lepage E et al. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res 1997; 3 (12 Pt 1): 2451-2458
(check this in PDF content)
38
Inoue K, Kamada M, Slaton JW et al. The prognostic value of angiogenesis and m etastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Clin Cancer Res 2002; 8 (6): 1863-1870
(check this in PDF content)
39
Alami J, W illiam s BR, Yeger H. Expression and localization of HGF and met in Wilms’ tumours. J Pathol 2002; 196 (1): 76-84
(check this in PDF content)
40
Stumm G, Eberwein S, R ostock-W olf S et al. Concomitant overexpression of the EGFR and erbB-2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis. Int J Cancer 1996; 69 (1): 17-22
(check this in PDF content)
41
Ghanem MA, van Steenbrugge GJ, Sudaryo MK et al. Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma. J Clin Pathol 2003; 56 (2): 107-113
(check this in PDF content)
42
Edgren M, Lennernas B, Larsson A, Kalkner K. Angiogenic factors: vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF) are not necessarily elevated in patients with advanced renal cell carcinom a. Anticancer Res 2001; 21(2B): 1423-1429
(check this in PDF content)
43
Schraml P, Struckmann K, Hatz F et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 2002; 196 (2): 186-193
(check this in PDF content)
44
Ottaiano A, Pisano C, De Chiara A et al. CD40 activation as potential tool in malignant neoplasms. Tumor 2002; 88 (5): 361-366
(check this in PDF content)
45
Ghanem M.A.,Van Der Kwast TN,Sudaryo MK. Expression and prognostic value of CD44 isoform s in nephroblastoma (Wilms tumor). J Urol 2002; 168 (2): 681-686
(check this in PDF content)
46
Miyake H, Eto H, Arakawa S et al. Over expression of CD44V8-10 in urinary exfoliated cells as an independent prognostic predictor in patients with urothelial cancer. J Urol 2002; 167 (3): 1282-1287
(check this in PDF content)
47
Rioux-Leclercq N, Epstein JI, Bansard JY et al. Clinical significance of cell proliferation, microvessel density, and CD44 adhesion molecule expression in renal cell carcinoma. Hum Pathol 2001; 32 (11): 1209-1215
(check this in PDF content)
48
Li N, Tsuji M, Kanda K et al. Analysis of CD44 isoform v10 expression and its prognostic value in renal cell carcinoma. BJU Int 2000; 85 (4): 514-518
(check this in PDF content)
49
Fischer C, Georg C, Kraus S et al. CD44s, E-cadherin and PCNA as markers for progression in renal cell carcinoma. Anticancer Res 1999; 19 (2C): 1513-1517
(check this in PDF content)
50
Alava E, Panizo A, Sola I et al. CD44v6 expression is related to progression in renal epithelial tum ours. Histopathology 1998; 33 (1): 39-45
(check this in PDF content)
51
Gunthert U, Stauder R, Mayer B et al. Are CD44 variant isoforms involved in human tumour progression? Cancer Surv 1995; 24: 19-42
(check this in PDF content)
52
G ilcrease MZ, Guzman-Paz M, Niehans G et al.Correlation of CD44S expression in renal clear cell carcinomas with subsequent tumor progression or recurrence. Cancer 1999; 86 (11): 2320-2326
(check this in PDF content)
53
Francois C, van Velthoven R, De Lathouwer et al. Galectin-1 and galectin-3 binding pattern expression in renal cell carcinomas. Am J Clin Pathol 1999; 112 (2): 194-203 84
(check this in PDF content)
54
Ghanem MA, Van Der Kwast TH, Den Hollander JC et al. Expression and prognostic value of epidermal growth factor receptor, transforming growth factor-alpha, and c-erb B-2 in nephroblastoma. Cancer 2001; 92 (12): 3120-3129
(check this in PDF content)
55
Ramp U, Jaquet K, Reinecke P et al. Acquisition of TGF- beta 1 resistance: an im portant progression factor in human renal cell carcinoma. Lab Invest 1997; 76 (5): 739-749
(check this in PDF content)
56
Papadopoulos I, W eichert-Jacobsen K, Wacker HH, Sprenger E. Correlation between DNA ploidy, proliferation m arker Ki-67 and early tum or progression in renal cell carcinoma. A prospective study. Eur Urol 1997; 31(1): 49-53
(check this in PDF content)
57
Haitel A, Wiener HG, Migschitz B et al. Proliferating cell nuclear antigen and M IB-1. An alternative to classic prognostic indicators in renal cell carcinomas. Am J Clin Pathol 1997; 107 (2): 229-235
(check this in PDF content)
58
Mitsumori K, Kittleson JM, Itoh N et al. Chromosome 14q LOH in localized clear cell renal cell carcinoma. J Pathol 2002; 198 (1): 110-114
(check this in PDF content)
59
Diakoumis E, Sourvinos G, Kiaris H et al. Genetic instability in renal cell carcinoma. Eur Urol 1998; 33 (2): 227­ 232
(check this in PDF content)
60
Willers CP, Siebert R, Bardenheuer W et al. Genetic instability of 3p12-p21-specific m icrosatellite sequences in renal cell carcinoma. Br J Urol 1996; 77 (4): 524-529
(check this in PDF content)
61
Terpe HJ, Storkel S, Zimmer U et al. Expression of CD44 isoforms in renal cell tumors. Positive correlation to tumor differentiation. Br J Urol 1997; 87 (4): 424-429
(check this in PDF content)
62
Cairns P, Tokino K, Eby Y, Sidransky D. Localization of tum or suppressor loci on chrom osom e 9 in prim ary human renal cell carcinomas. Cancer Res 1995; 55 (2): 224-227
(check this in PDF content)
63
Polascik TJ, Cairns P, Epstein JI et al. Distal nephron renal tumors: m icrosatellite allelotype. Cancer Res 1996; 56 (8): 1892-1895
(check this in PDF content)
64
Fujioka T, Hasegawa M, Suzuki Y et al. Telomerase activity in human renal cell carcinoma. Int J Urol 2000; 7 (1): 16-21
(check this in PDF content)
65
Dahse R, Fiedler W, Junker K et al. Telomerase activity and telom ere lengths: alterations in renal cell carcinomas. Kidney Int 1999; 56 (4): 1289-1290
(check this in PDF content)
66
Tuzel E, Kirkali Z, Yorukoglu K et al. Metallothionein expression in renal cell carcinoma: subcellular localization and prognostic significance. J Urol 2001; 165 (5): 1710-1713
(check this in PDF content)
67
Wang L, Darling J, Zhang JS et al. Incidence of apoptosis and m etallothionein expression in renal cell carcinoma. Oncogene 1998; 16 (5): 635-642
(check this in PDF content)
68
Braun C, Engel M, Seifert M et al. Expression of calpain I messenger RNA in human renal cell carcinoma: correlation with lymph node metastasis and histological type. Int J Cancer 1999; 84 (1): 6-9
(check this in PDF content)
69
Takenawa J, Kaneko Y, Kishishita M et al. Transcript levels of aquaporin 1 and carbonic anhydrase IV as predictive indicators for prognosis of renal cell carcinoma patients after nephrectomy. Jpn J Cancer Res 1994;89(3): 324-329
(check this in PDF content)
70
Takashi M, Sakata T, Kato K. Use of serum gamma- enolase and aldolase A in combination as markers for renal cell carcinoma. Jpn J Cancer Res 1993; 84 (3): 304-309
(check this in PDF content)
71
Kitamura Y, Watanabe M, Komatsubara S, Sakata Y. Urinary excretion of glycine.prolile dipeptidile aminopeptidase, N-acetyl-beta-D -glucosam inidase, alanine am inopeptidase and low molecular protein in patients with renal cell carcinoma. Hinyokika Kiyo 1990; 36 (5): 535-539
(check this in PDF content)
72
Nakagawa Y, Sirivongs D, Novy MB et al. Nephrocalcin: biosynthesis by human renal carcinom a cells in vitro and in vivo. Cancer Res 1999; 52 (6): 1573-1579
(check this in PDF content)
73
Balitskaia OV, Berdinskikh NK, Kononenko NG. The possibilities of using the free polyam ines of the peripheral blood as biochem ical tum or m arkers in nephroblastom a in children. Vopr Onkol 1992; 38 (6): 674-682 Поступила в редакцию 22.11.2005 г.
(check this in PDF content)